Ozette Technologies specializes in advanced computational analysis of single-cell immune data, leveraging modern flow cytometry methods to unlock insights that drive therapeutic development. Their technology addresses the limitations of traditional data analysis by providing unmatched speed, resolution, and depth in data interpretation. By employing interpretable machine-learning methods and cloud computing, Ozette transforms raw immune data into comprehensive, annotated cell populations, enabling researchers to discover low-abundance and previously uncharacterized phenotypes. This capability significantly accelerates the pace of research and development in immunology, particularly in the context of cancer drug development.

The company’s innovative solutions include their Endpoints technology, which streamlines the identification of biomarker endpoints for clinical trials, and their Discovery technology, which automates the full cell population discovery process. These tools facilitate high-quality, reproducible analyses that inform drug characterization, dosing, and efficacy. Ozette's vertically integrated approach combines state-of-the-art immunology labs with advanced analysis technology, ensuring that partners can maximize the value of their data. By fostering collaborative research partnerships, Ozette aims to drive advancements in the therapeutic landscape, ultimately contributing to more effective and targeted treatments for patients.

United States

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

Ozette Technologies

Company Details